Tredje AP fonden bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 4,520 shares of the medical device company’s stock, valued at approximately $331,000.

A number of other large investors have also modified their holdings of the stock. Rathbone Brothers plc raised its position in DexCom by 5.3% in the 2nd quarter. Rathbone Brothers plc now owns 4,000 shares of the medical device company’s stock worth $293,000 after purchasing an additional 200 shares during the period. Pier Capital LLC raised its position in DexCom by 104.2% in the 2nd quarter. Pier Capital LLC now owns 6,720 shares of the medical device company’s stock worth $492,000 after purchasing an additional 3,429 shares during the period. Rosenblum Silverman Sutton S F Inc. CA raised its position in DexCom by 783.0% in the 2nd quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 69,586 shares of the medical device company’s stock worth $5,090,000 after purchasing an additional 61,705 shares during the period. Delta Lloyd Asset Management N.V. purchased a new position in DexCom in the 2nd quarter worth $738,000. Finally, Swiss National Bank raised its position in DexCom by 2.8% in the 2nd quarter. Swiss National Bank now owns 307,900 shares of the medical device company’s stock worth $22,523,000 after purchasing an additional 8,400 shares during the period.

A number of equities analysts have issued reports on the stock. BMO Capital Markets restated an “outperform” rating and issued a $90.00 price objective (down previously from $105.00) on shares of DexCom in a research report on Wednesday, August 2nd. BidaskClub upgraded shares of DexCom from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 9th. Robert W. Baird restated a “hold” rating and issued a $79.00 price objective on shares of DexCom in a research report on Sunday, September 10th. Piper Jaffray Companies restated an “overweight” rating and issued a $78.00 price objective (down previously from $87.00) on shares of DexCom in a research report on Wednesday, August 16th. Finally, ValuEngine upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $86.87.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/09/16/tredje-ap-fonden-buys-new-stake-in-dexcom-inc-dxcm.html.

In other DexCom news, EVP Andrew K. Balo sold 3,200 shares of the stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $71.55, for a total transaction of $228,960.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $69.47, for a total transaction of $100,731.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,223 shares of company stock worth $1,881,249. 1.70% of the stock is owned by company insiders.

Shares of DexCom, Inc. (NASDAQ DXCM) opened at 70.29 on Friday. The company’s 50-day moving average is $72.47 and its 200 day moving average is $74.11. DexCom, Inc. has a 1-year low of $57.68 and a 1-year high of $94.79. The company’s market cap is $6.08 billion.

DexCom (NASDAQ:DXCM) last issued its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The company had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. During the same period in the prior year, the business earned ($0.24) EPS. The firm’s quarterly revenue was up 24.3% on a year-over-year basis. Equities analysts anticipate that DexCom, Inc. will post ($0.77) EPS for the current year.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.